Avalon globocare and university of natural resources and life sciences (boku) co-develop innovative in-silico technology, enabling the design and synthesis of novel cell membrane receptor targets for cancer and immune-related diseases

Freehold, n.j., oct. 07, 2021 (globe newswire) -- avalon globocare corp. (nasdaq: avco) (avalon or the company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced co-development of a novel, cell-free, in-silico system to facilitate the company's drug development efforts, together with the institute for synthetic bioarchitectures at the university of natural resources and life sciences (boku) in vienna, austria. a study of the new technology was featured in the september 2021 issue of membranes, an international, peer-reviewed journal.
AVCO Ratings Summary
AVCO Quant Ranking